In this paper, we develop a mathematical model that enables the investigation of the production and intracellular transport of amyloid precursor protein (APP) and tau protein in a neuron. We also investigate the aggregation of APP fragments into amyloid-β (Aβ) as well as tau aggregation into tau oligomers and neurofibrillary tangles. Using the developed model, we investigate how Aβ aggregation can influence tau transport and aggregation in both the soma and the axon. We couple the Aβ and tau agglomeration processes by assuming that the value of the kinetic constant that describes the autocatalytic growth (self-replication) reaction step of tau aggregation is proportional to the Aβ concentration. The model predicts that APP and tau are distributed differently in the axon. While APP has a uniform distribution along the axon, tau's concentration first decreases and then increases towards the synapse. Aβ is uniformly produced along the axon while misfolded tau protein is mostly produced in the proximal axon. The number of Aβ and tau polymers originating from the axon is much smaller than the number of Aβ and tau polymers originating from the soma. The rate of production of misfolded tau polymers depends on how strongly their production is facilitated by Aβ.
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Introduction
Alzheimer's disease (AD) is a common neurodegenerative disorder that accounts for 60-70% of dementia cases [1] . It is especially common in elderly people, which means that AD will be an even greater challenge in the future because of population ageing. The number In displaying possible mechanisms of tau transport, we followed [7] (see fig. 3 in [7] ). Aggregation of APP fragments into Aβ and aggregation of hyperphosphorylated tau protein into NFTs is also shown. (Online version in colour.)
of people with AD in the USA alone in 2015 exceeded 5 million people and this number is expected to triple by 2050 [2] . What makes research in this field even more pertinent is that there are currently no curative treatments for AD [3] [4] [5] [6] .
Two main hallmarks of AD are extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs) (figure 1). The amyloid plaques are produced by aggregation of amyloid-β (Aβ) peptide, which is generated by the abnormal cleavage of amyloid precursor protein (APP) [8] [9] [10] . NFTs are composed of misfolded tau protein, a microtubule (MT)-associated protein that in AD and other tauopathies becomes hyperphosphorylated, detaches from MTs and aggregates to form intra-neuronal deposits [11] [12] [13] [14] .
There are several hypotheses explaining the mechanism of AD development, the most common of which attributes AD development to failure to clear the Aβ aggregates from the brain. According to this hypothesis, Aβ deposition initiates a cascade of events (including tau pathology) that leads to AD [15] . The strongest support for the amyloid cascade hypothesis comes from Aβ involvement in the inherited form of AD, which is characterized by an early onset of the disease [16] . Several mechanisms were suggested to explain the effects of extracellular Aβ on tau misfolding and agglomeration inside neurons [17] .
The enthusiasm about the amyloid cascade hypothesis [18] was dampened by the failure of several therapeutic agents, designed to reduce Aβ levels, in phase III clinical trials [19] [20] [21] . Karran et al. [15] reviewed recent unsuccessful attempts to develop treatments for AD; no new drugs for treatment of AD have been approved since 2003 [1] .
Karran et al. [15] hypothesized that Aβ may serve as a trigger for AD development and thus administering such therapeutics at a later stage of the disease will not affect the disease progression. Additional data supporting the hypothesis that Aβ aggregation may accelerate tau pathology were reviewed in [17] .
Mathematical modelling is a powerful tool that can be used to uncover the physical consequences of various biological hypotheses. It may be difficult to experimentally test a hypothesis directly, whereas it is easier to design a mathematical model that is based on a certain hypothesis and see whether this hypothesis leads to biologically reasonable predictions.
In our previous paper [22] , we investigated the tau hypothesis, which assumes that tau agglomeration precedes Aβ agglomeration and that misfolded tau polymers may trigger Aβ agglomeration. In this paper, we concentrate on the alternative hypothesis, the amyloid cascade hypothesis, which assumes that the deposition of Aβ in the brain initiates a cascade of events which lead to AD. This cascade of events includes the development of tau pathology [15] .
In [22] , we only simulated tau and APP transport in the axon. Here, we develop a model describing the production and accumulation of these proteins in the soma; we then combine the two models, thus producing a model that simulates the whole neuron. We develop equations that simulate Aβ aggregation in the axon and soma (in [22] it was done only for tau). We also develop a phenomenological model simulating the effect of Aβ on tau misfolding and agglomeration. Our goal is to investigate how the amyloid cascade hypothesis affects transport of APP and tau in a neuron, agglomeration of APP fragments into Aβ and agglomeration of tau into NFTs [23] .
We investigate the situation in which Aβ and tau protein begin to agglomerate in the soma and the axon. We examine how Aβ aggregation can potentially affect transport and aggregation of tau. We model aggregation of both Aβ peptide and tau by the minimalistic two-step Finke-Watzky (F-W) model. In the F-W model, the aggregate is interpreted as an average polymer, representing many different fibril sizes. For a given peptide or protein, the model includes only two kinetic constants, k * 1 and k * 2 , which are the average rate constants describing nucleation and autocatalytic growth, respectively. Although there are more accurate models describing protein aggregation [24] , the F-W model was shown to fit protein aggregation data in various neurological systems sufficiently well [25, 26] .
Materials and models (a) Model of APP transport and Aβ aggregation
The model that we used for simulating APP transport is based on the fast axonal transport model developed in [27, 28] . We assumed that APP is transported in presynaptic vesicles [29] . Such vesicles can move anterogradely and retrogradely [30] . figure 2a) . Because of a large size of APP-transporting vesicles (each vesicle carries at least several hundred APP molecules [32] ), we neglected the diffusivity of the vesicles. The diffusivity of individual APP molecules was neglected because the molecules are enclosed inside the vesicles.
The conservation of APP molecules contained in the presynaptic vesicles that are detached from MTs is expressed by the following equation:
The first four terms in equation (2.3) are kinetic terms describing transitions between anterogradely running, retrogradely running and free kinetic states (figure 2a). The last two terms in equation (2.3) describe Aβ production using the F-W model. The Aβ plaques are produced by aggregation of Aβ peptide that is generated by APP cleavage by β-and γ-secretases; this process occurs at the plasma membrane of both the soma and axon. This is different from the normal processing of APP, which involves α-and γ-secretases [8] [9] [10] . The mechanism of Aβ aggregation combines primary nucleation (described by the kinetic constant k * 1,ax in equation (2.3)) and secondary nucleation (described by the kinetic constant k * 2,ax ) pathways and involves a catalytic mechanism that couples the formation of amyloid fibrils and small diffusive aggregates of the peptide [33] . We did not include any terms involving the APP half-life in equation (2. 3) because APP is expected to be largely protected by presynaptic vesicles during axonal transport and the protein destruction machinery is also not abundant in axons.
The total concentration of APP in the axon can be calculated by taking the sum of the anterogradely transported, retrogradely transported and detached from MTs APP concentrations (figure 2a), Accumulation of extracellular Aβ polymers originating from APP processing at the axon membrane is described by the following equation:
where the last term on the right-hand side of equation (2.5) simulates Aβ degradation (Aβ plaques can be removed by phagocytosis [34] ). Our model simulates intercellular transport inside a neuron. As Aβ aggregates in the extracellular space, we did not simulate its transport. This is a limitation of the present model, especially in light of significant research by Waters [35] , who investigated the effect of diffusion and the half-life of soluble (diffusible) Aβ on its distribution in the extracellular space within brain tissue. Our model should be extended to account for Aβ transport in the extracellular space in future research, especially because Aβ peptides are easily diffusible [36] . Aggregation of Aβ is a very slow process that takes years or even decades, which is much slower than the time scale of APP transport towards the synapse (which at most takes days for the longest axons). Therefore, we assumed that the APP concentration profiles in various kinetic states assume their steady-state distributions and wrote equations (2.1)-(2.3) as steadystate equations. We retained the transient term on the left-hand side of equation (2.5) in order to simulate slow accumulation of Aβ. The total number of Aβ polymers originating from APP processing at the axon membrane can be found as
In the soma, we calculate the number of molecules rather than their linear number density. The conservation of APP molecules synthesized in the soma is expressed by the following equation:
where the first term on the right-hand side of equation (2.7) simulates APP synthesis in the soma, the second and third terms simulate the production of Aβ polymers from APP, the fourth term simulates APP destruction due to the APP finite half-life in the soma (which is expected to occur much faster than the loss of APP owing to production of Aβ polymers) and the fifth term simulates the APP flux from the soma to the axon. Accumulation of extracellular Aβ polymers originating from APP processing at the soma membrane is simulated by the following equation:
The total number of Aβ polymers produced by one neuron (by APP processing at the axon and soma membranes) is calculated as
Equations (2.1)-(2.3) and (2.5)-(2.7) are solved subject to the following boundary and initial conditions. As APP is synthesized in the soma, at the axon hillock we postulate the total APP flux that enters the axon from the soma,
Note that j * tot,APP (0) is the net APP flux, the anterograde flux of APP that enters the soma minus the retrograde flux of APP that returns to the soma for degradation.
At the axon terminal, we assume that a portion of APP flux that enters the axon (calculated as σ c * + (L * )) returns to the axon via the retrograde flux. This process probably involves changing kinesin to dynein motors at the terminal,
It is assumed that initially the neuron is healthy, and extracellular concentrations of Aβ polymers are therefore zero at t* = 0,
We estimated values of h * APP and C * s,i by stating conservation of APP in the soma:
As Niederst et al. [37] reported that approximately 40% of the total secretion of Aβ occurs from the axon, we also stated that 
(c) Model of tau protein transport and aggregation
Tau protein is transported by slow axonal transport [38] [39] [40] , diffusion in the cytosol [41] [42] [43] and one-dimensional diffusion along the MT lattice [44] . The active (slow axonal transport) mechanism dominates at longer distances and larger time scales [44] . Unlike APP, which moves in the axon with an approximately constant velocity, slow axonal transport of tau does not occur continuously; rather, short periods of tau's rapid motion on MTs are interrupted by long pauses. It should be noted that our model is a cargo-level model; we use phenomenological equations to describe the behaviour of tau as a cargo. We do not simulate particular events causing cargo pausing [45] . This would require going one level higher in model complexity and simulating such processes as detachment and reattachment of motors to MTs as well as whether the motors are coordinated or there is a tug-of-war between the motors [46] . Dependent variables in the model of tau transport are given in electronic supplementary material, table S4, and model parameters describing tau transport are given in electronic supplementary material, table S5. In our model, we assumed that normal tau can be in seven kinetic states: actively moving on MTs by kinesin and dynein motors (tau concentrations n * a and n * r , respectively), pausing while still maintaining its connection to kinesin and dynein motors and ready to resume its motion (tau concentrations n * a0 and n * r0 , respectively), freely suspended in the cytosol (tau concentration n * free ), diffusing along MTs (tau concentration n * dif ) and stationary on MTs (tau concentration n * st ). In addition, tau can become hyperphosphorylated, misfold, form polymers of various sizes and aggregate. The concentration of misfolded tau in the axon is n * mis,ax (figure 2b). The tau concentrations in the axon are represented by the linear number densities of tau molecules in various kinetic states (μm −1 ).
The conservation of actively transported tau gives the following equations:
The first terms on the left-hand sides of equations (2.15) and (2.16) simulate tau transport by anterograde (kinesin) and retrograde (dynein) motors, respectively. According to Scholz & Mandelkow [7] , during periods of its active transport tau can be either pulled by a molecular motor directly or reside on a small piece of an MT which is pulled by a motor. The other terms in equations (2.15) and (2.16) represent tau transitions between actively transported and pausing kinetic states.
The conservation of pausing tau gives the following equations:
and
In the pausing states, tau does not move and all terms in equations (2.17) and (2.18) are kinetic terms, simulating tau transitions between various kinetic states.
The conservation of tau freely suspended in the cytosol gives the following equation:
The first term on the left-hand side of equation (2.19) simulates tau transport by diffusion in the cytosol, the two terms before the last term describe tau conversion to the misfolded state (according to the F-W model) and the last term describes tau's degradation owing to tau's finite 
Agglomeration of misfolded tau is described by the following equation: [47] . The conservation of a sub-population of MT-bound tau that can diffuse along the MTs gives the following equation:
The first term on the left-hand side of equation (2.21) simulates tau's diffusion along the MTs and the other terms simulate tau transitions between various kinetic states. The conservation of a sub-population of stationary tau bound to MTs gives the following equation:
Because stationary tau does not move, all of the terms in equation (2.22) are kinetic terms, expressing tau transitions between various kinetic states (figure 2b). The total tau concentration is calculated as the sum of tau concentrations in all eight kinetic states shown in figure 2b ,
The percentage of MT-bound tau is calculated as the sum of tau concentrations in six MT-bound states over the total tau concentration,
The total flux of tau is calculated as the sum of the diffusion fluxes (of free tau suspended in the cytosol and MT-bound tau that can diffuse along the MT lattice) and the fluxes owing to actively transported tau, which can move anterogradely and retrogradely,
As we suggested in [48] , the average velocity of tau protein was determined by finding the ratio of the total flux of tau to its total concentration,
The number of tau polymers in the whole axon can be calculated as
Stating the conservation of tau molecules in the soma gives the following equation:
The first term on the right-hand side of equation (2.28) simulates tau production in the soma, the second and third terms simulate tau aggregation into tau oligomers and NFTs, the fourth term simulates tau degradation (primarily in proteasomes [49] [50] [51] ) and the fifth term simulates the flux of tau from the soma into the axon. 
The initial conditions for the concentrations of misfolded tau protein in the axon and in the soma and for the number of tau protein molecules in the soma are, respectively, fig. 7D of [56] . Experimental results reported in [56] were rescaled such that n tot at x* = 0 was set equal to unity. We only show the points from fig. 7D of [56] that were between 0 and 600 µm away from the soma. Black et al. [56] also reported a few points of tau concentrations for x* > 600 µm, which are within the synapse. These points are not displayed because our model does not simulate the biochemistry occurring in the synapse. Case of β * ax = β s = 0. (Online version in colour.)
We assumed that approximately 80% of tau produced in the soma enters the axon, the rest is destroyed in proteasomes. Note that because h * tau characterizes the total flux of tau that enters the axon (anterograde minus retrograde flux), In equation (2.40) , the concentration of tau monomers in the axon was estimated as follows. The volume of the axon is A * ax L * and the number of tau molecules in the axon can be estimated as (N * s /V * s )A * ax L * , so the concentration of tau molecules in the axon is (N * s /V * s )A * ax . Since the exact mechanisms by which Aβ induces tau aggregation are not fully understood [17] , in order to simulate the effect of Aβ on tau agglomeration we used a minimalistic approach and assumed that the increases of λ * 2,ax and λ * 2,s are linearly correlated with the concentration of Aβ in the axon and in the soma, respectively. This assumption leads to (2.29) are ordinary differential equations containing the derivatives with respect to t*. These equations must be solved subject to initial conditions (2.12) and (2.35). Equations (2.5) and (2.20) describe aggregation of Aβ and misfolded tau, respectively, resulting from processing of these proteins in the axon. Equations (2.7) and (2.28) describe accumulation of APP and tau, respectively, in the soma. Equations (2.8) and (2.29) describe aggregation of Aβ and misfolded tau, respectively, resulting from processing of these proteins in the soma. All of the above processes are characterized by extremely slow variations that take many years, which is much greater than the typical time scale characterizing APP and tau transport along the axon (at most weeks). This allowed us to separate the time scales and solve equations (2.5), (2.7), (2. n * mis,ax (x * ) are functions of x*, they are both initially zero because we assumed that a healthy axon has neither Aβ nor misfolded tau. At the first step of the solution procedure, we used the initial values given by equations (2.12) and (2.35) to determine the distributions of APP and tau by using the quasi-steady-state approximation (QSSA) [53, 54] . The QSSA assumes that changes in c * Aβ,ax , C * s , C * Aβ,s , n * mis,ax , N * s and N * mis,s are sufficiently slow such that the APP and tau distributions have enough time to relax to their steady-state profiles. The following describes how the steady-state APP and tau profiles were found.
Equations ( equations (2.3), (2.17), (2.18) and (2.22) were used to eliminate n * a0 (x * ), n * r0 (x * ), n * st (x * ) and c * 0 (x * ) from the remaining equations, and the boundary value problem for the remaining equations, together with boundary conditions (2.10), (2.11), (2.31) and (2.33), was solved by using Matlab's BVP4C solver (Matlab R2017b, MathWorks, Natick, MA, USA).
After finding the APP and tau distributions at t* = 0, time was advanced by a time step t*, and c * Aβ,ax (x * ), C * s , C * Aβ,s , n * mis,ax (x * ), N * s and N * mis,s were obtained for a new time by integrating equations (2.5), (2.7), (2.8), (2.20) , (2.28) and (2.29) . Then the steady-state problem given by equations (2.1)-(2.3) and (2.15)-(2.19), (2.21) and (2.22) was solved again. This procedure was repeated until c * Aβ,ax (x * ), C * s , C * Aβ,s , n * mis,ax (x * ), N * s and N * mis,s reached their steady-state values, which corresponds to the situation when the production of Aβ, monomeric tau and misfolded tau is balanced by the destruction of these substances because of their finite half-lives. We used a standard L 2 distance to measure distances between various concentrations [55] . The time step independence was verified by systematically decreasing t*, and convergence to steady state was verified by systematically increasing the final time. 
Results
The model predicts that the total APP concentration is constant along the axon (figure 3a). It also predicts that the total concentration of tau monomers along the axon decreases with the increased distance from the soma and then increases after a certain distance. This agrees with experimental measurements reported in [56] (figure 3b). Figure 3a ,b also shows that APP and tau concentrations do not deviate from their steady-state distributions, which is explained by very slow aggregation of Aβ and misfolded tau at the onset of AD.
The concentration of extracellular Aβ polymers originating from the axon is uniformly distributed along the axon's length (figure 4a). This is explained by the fact that Aβ polymers are produced from free APP, the concentration of which is also uniformly distributed along the axon's length (figure 5a). The concentration of misfolded tau polymers increases with time until it reaches a steady-state distribution, when the production and destruction of misfolded tau are equal (figure 4b). At any given time, the maximum concentration of misfolded tau polymers occurs in the proximal axon (figure 4b). This is because misfolded tau polymers are produced from free tau monomers (equation (2.20) ), the concentration of which also peaks in the proximal axon (figure 5b). The number of APP molecules in the soma stays constant as time progresses (figure 6a) while the number of tau monomers decreases (figure 6b) because they convert into tau polymers. The decrease is larger for greater values of β * ax and β s because these parameters determine how significantly the Aβ aggregation affects tau aggregation (equations (2.41) and (2.42) ). In our model, the Aβ aggregates do not influence APP transport into the axon, which explains the lack of dependence of C s on β * ax and β s in figure 6a. The number of extracellular Aβ polymers originating from the axon, C Aβ,ax , is obtained by integrating the distribution of these polymers displayed in figure 4a with respect to the axon's length. C Aβ,ax quickly increases until it reaches the steady-state value (figure 7a). There is no dependence on β * ax and β s in figure 7a because these parameters do not influence APP transport. The number of misfolded tau polymers in the axon (the quantity obtained by integrating the distribution of tau polymers displayed in figure 4b) has a maximum and then slightly decreases until reaching a plateau forβ * ax andβ s equal to 10 4 and 10 5 (figure 7b). The decrease of N mis,ax with the increase of β * ax and β s in figure 7b is explained by the decreasing number of tau monomers in the soma with the increase of β * ax and β s (figure 6b); thus, less tau enters the axon and so fewer tau monomers are available to aggregate.
The number of extracellular Aβ polymers originating from the soma, C Aβ,s , is much larger than of those originating from the axon, C Aβ,ax . C Aβ,s increases with time (figure 8a) but does not reach its steady-state value as quickly as the number of extracellular Aβ polymers originating from the axon (compare figure 8a with figure 7a ). The number of misfolded tau polymers in the soma increases with time and reaches higher steady-state values for larger values of β * ax and β s owing to higher tau agglomeration rates; see equations (2.41) and (2.42).
The behaviours of C Aβ,tot and N mis,tot displayed in figure 9a and b are similar to the behaviours of the number of extracellular Aβ and tau polymers originating from the soma (displayed in figure 8a and b) , respectively. This is because the soma contains most of the misfolded polymers of both types.
Conclusion and future directions
We developed a model that simulates the interplay of APP transport and agglomeration of APP fragments into Aβ, on one hand, and tau protein transport and aggregation, on the other. The model is developed by stating conservations of APP and tau in various kinetic states, separately in the axon and soma. Following previously published experimental results, we assumed that APP is transported in the axon by fast axonal transport while tau is transported in the axon by the slow axonal transport mechanism. We also assumed that the formation of Aβ enhances tau agglomeration by increasing the kinetic constant that simulates the autocatalytic growth (selfreplication) reaction step of tau aggregation.
The model simulates the concentrations of APP and tau monomers in the axon and soma, the concentrations of Aβ resulting from aggregation of APP fragments generated at the axon and soma membrane, and the concentrations of agglomerated tau in the axon and soma. The model makes the following predictions, which are both testable and falsifiable.
(1) APP that is present in the axon is uniformly distributed along the axon length. Contrary to this, tau monomers exhibit a complicated distribution along the axon length: the concentration of tau monomers first decreases, goes through a minimum and then increases towards the synapse. (2) A much larger number of Aβ polymers are produced at the soma membrane than at the axon membrane. (3) A much larger number of tau polymers are produced in the soma than in the axon. The tau polymers produced in the axon are mostly produced in the proximal axon. (4) The assumption that the presence of Aβ enhances the rate of tau aggregation through the secondary nucleation mechanism results in a reduction of the number of tau monomers present in the soma and an increase in the rate of production of tau polymers in the soma. The rate of production of tau polymers in the axon remains small. (5) The total number of Aβ and misfolded tau polymers in the axon and soma increases with time until they reach their steady-state concentrations, determined by the balance between generation and destruction of the polymers. This conclusion is based on the assumption that the half-lives of Aβ and misfolded tau do not change with time. This assumption needs to be improved in the future because functioning of degradation machinery may be negatively affected by the accumulation of Aβ and misfolded tau; for example, tau oligomers may plug the entrance to proteasomes. (6) Our simulations suggest that transport processes in neurons may not be affected to a significant degree at the onset of AD by agglomeration of Aβ and misfolded tau. This gives hope that early interventions in AD may be successful in stopping the development of this devastating disease. Future research should address incorporating the effects of Aβ and misfolded tau accumulation on the rates of APP and tau production and destruction as well as the effect of diffusion transport of oligomeric species on Aβ distribution. Future research should also rely on a model that, unlike the F-W model, can discriminate between oligomeric and fibrillary species of Aβ and tau, because those species exhibit different degrees of neurotoxicity. Transport of Aβ in the extracellular space, especially by diffusion, should also be incorporated in future models. This should account for different diffusivities of different Aβ species, such as monomers, oligomers and plaques; the last are probably immobile. So far, validation of our theoretical model has been limited to comparisons with published data on tau concentration (figure 3b) and average tau velocity ( fig. S2b in [31] ). Future work should include more experimental validation, especially for the APP concentration and the rates of tau and Aβ aggregation.
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